News

2017 Breaks Bioscience Records

Tuesday, December 12, 2017

 

New Partnership Creates the Broadest Suite of Capabilities and Innovative Solutions Available for the Study and Diagnosis of Complex Genetic Variations in Cancer.

Friday, December 08, 2017

 

Sharklet Moves Out of the Startup Scene

Tuesday, December 05, 2017

 

Cetya Therapeutics Announces Advanced Industries Award

Friday, December 01, 2017

$170,000 Colorado Grant will advance Cetya’s novel targeted HDAC inhibitor program 

Regenerative Medicine in Colorado

Tuesday, November 28, 2017

 

Layne Los, PhD, CEO of ClaroLabs announced the company has raised $800K in the first round of a $2M Series A preferred stock offering

Monday, November 27, 2017

Layne Los, PhD, CEO of ClaroLabs announced the company has raised $800K in the first round of a $2M Series A preferred stock offering. The company recently setup operations in a 5000+ sq. ft. facility in Lafayette, CO. Claro Scientific Laboratories, Inc is a clinical reference Lab (CLIA) providing urine drug testing services for Addiction Recovery Clinics, Pain Clinics and a Direct to Consumer service.

For people with Substance Use Disorder (SUD, diagnosed or not) knowing unequivocally if a loved one is using is one of the first steps in the recovery process. Unlike other less sophisticated tests, our service detects 152 drugs, many days if not weeks, after drug use (depending on the drug and dose). ClaroLabs will be accepting samples in January 2018.

For more information and to order a test kit, visit clarolabs.com.


 
Continue Reading

Ready for Retirees

Tuesday, November 14, 2017

 

miRagen Therapeutics to Participate in Four Investor Conferences in November

Monday, November 13, 2017

miRagen Therapeutics, Inc. (NASDAQ:MGEN) a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a company overview at the following conferences in November. 

miRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update

Monday, November 13, 2017

  

Former Array Biopharma COO, Dr. David L. Snitman joins AmideBio Business Advisory Board

Monday, November 13, 2017

AmideBio LLC, a privately-held biopharmaceutical company, announced today that Dr. David L. Snitman has joined its business advisory board. Dr. Snitman has extensive experience with company financing as well as building strategic alliances with the pharmaceutical industry. He will be a huge asset to the company as it develops its pipeline of novel drugs targeting diabetes and other metabolic diseases.

“We are delighted to have Dr. Snitman join the AmideBio Advisory Board as we develop our pipline of drug candidates targeting serious unmet medical needs,” said Dr. Misha Plam, President and CEO of Amide Bio.“Dr. Snitman’s knowledge of pharmaceutical drug development and financing, combined with his extensive experience in negotiating and managing strategic partnerships across the pharmaceutical industry will be immensely valuable to us.“

“I am excited to be joining AmideBio’s advisory board. The Company has an impessive pipeline of drug candidates that could significantly impact the way diabetes and congenital hyperinsulinism are treated,” said Dr. David L. Snitman. “I am impressed by the quality and novelty of research at AmideBio as well as the team driving to help patients afflicted with these treatment-challenged diseases.”

Dr. Snitman is currently a principal at DL SNITMAN LLC, a consulting firm providing business development services to the biotechnology industry. Dr. Snitman is a co-founder of Array BioPharma and served as Chief Operating Officer & Vice President, Business Development from 1998 to 2015. He was a member of Array’s Board of Directors from May 1998 to October 2012. Prior to forming Array, Dr. Snitman held senior positions with Amgen Inc. including Associate Director, New Products and Technology, and Manager of Amgen's Boulder research facility. Dr. Snitman received a B.S. in chemistry from Northeastern University and obtained a Ph.D. in the synthesis of natural products from the University of Colorado. He was an NIH Postdoctoral Fellow at the Massachusetts Institute of Technology.

 
Continue Reading